Uncategorized

Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo

Altamira Therapeutics today reported highlights from a peer reviewed article showing efficacy of oral betahistine in the treatment of posterior canal benign paroxysmal positional vertigo (BPPV) when administered along with a canal repositioning procedure, the Epley maneuver.

Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo Read More »

Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program

Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).

Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program Read More »

Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll, M.D.

Babson Diagnostics today announced the addition of a clinical advisor who will bring valuable insights of the medical community in the ongoing development and introduction of the company’s new diagnostic blood testing service, BetterWay™. Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice

Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll, M.D. Read More »

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus

JW Therapeutics announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of relmacabtagene autoleucel injection (relma-cel) in patients with moderately or severely refractory systemic lupus erythematosus (SLE).

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus Read More »

REGENATIVE LABS TO PRESENT ITS GROUNDBREAKING WHARTON’S JELLY STUDIES AT THE SYMPOSIUM ON ADVANCED WOUND CARE

Regenative Labs announced that it will present two scientific studies demonstrating the efficacy of Wharton’s jelly allografts in complicated post-surgical wounds and late-stage sacral decubitus ulcers at the Symposium on Advanced Wound Care (SAWC) conference.

REGENATIVE LABS TO PRESENT ITS GROUNDBREAKING WHARTON’S JELLY STUDIES AT THE SYMPOSIUM ON ADVANCED WOUND CARE Read More »

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke.

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke Read More »

Scroll to Top